Technology
Technology
Nexavant®
Nexavant®, the novel TLR3 agonist
-
1 A defined TLR3 agonist with homogeneity
-
2 RNase A and heat resistant
-
3Stable for more than two years at 42℃
-
4 TLR3 and RIGI agonist without MDA5 activation
-
5 Scale-up production in GMP grade
-
6 CAS registered (CAS Number: 2839526-76-8)
-
7 More than 99% purity in HPLC
-
8 Capable for more than 10 million dose production/year
-
9 Strong immune stimulant: https://pubmed.ncbi.nlm.nih.gov/36761735/
-
10 Potent anticancer effect: https://pubmed.ncbi.nlm.nih.gov/38136298/
-
11 Induce Th1 and CTL response
-
12 DS for the following development:
-
Vaccine adjuvant
-
Anti PD-1 dual therapy
-
Adjuvant for a cross-reactive flu vaccine
-
Peptide complex drug development
-
13 solid scientific evidences
-
Ko et al., 2023 Frontier immunology: vaccine adjuvant https://pubmed.ncbi.nlm.nih.gov/36761735/
-
Lee et al., 2023 Cancers: anticancer effect https://pubmed.ncbi.nlm.nih.gov/38136298/
-
Ko et al., 2024 Nature Communications: universal flu vaccine https://www.nature.com/articles/s41467-024-54620-4
-
Ko et al., 2025 NPJ Vaccines: TB vaccine adjuvant https://www.nature.com/articles/s41541-025-01225-7
-
Kim et al., 2025 ACS Nano: anticancer application https://pubs.acs.org/doi/10.1021/acsnano.5c10081
-
Ko et al., 2025 NPJ Vaccines: peptide vaccine adjuvant https://www.nature.com/articles/s41541-025-01349-w
-
Ko et al., 2026, Frontiers in Immunology: nasal vaccine adjuvant https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1745319/full
Nexavant®, a homologous, stable, and high purity product
-
Homogeneity
-
Stability I
-
Purity
-
Stability II
